TDP 43 News and Research

RSS

Researchers determine atomic interactions that stabilize phase-changing proteins

Most of the well-studied proteins in our bodies are like metal; some can change shape easily, like aluminum foil, and others are rigid, like steel beams, but they typically have a solid, well-defined structure.

2 Jul 2019

Protein Clumps In ALS Neurons Provide Potential Target For New Therapies

Amyotrophic lateral sclerosis is a neurological condition that affects motor neurons -- the nerve cells that control breathing and muscles.

2 Jul 2019

ALS mobility and survival could be improved by increasing glucose

Researchers from University of Arizona have come up with a new study that shows that increasing the amount of glucose that could be transformed into energy could help persons with amyotrophic lateral sclerosis (ALS) by improving their mobility and increasing their survival rates.

26 Jun 2019

Scientists describe how cells 'decide' between pluripotency and differentiation

Induced pluripotent stem cells can turn into any type of cell in the body or remain in their original form. In the current edition of Molecular Cell, scientists from the Helmholtz Zentrum München describe how cells “decide” which of these two directions to take.

3 May 2019

New type of dementia is '100 times more common' than ALS

Physicians have defined a new form of dementia that may be more common than Alzheimer’s disease. The condition, named LATE, affects a different part of the brain.

1 May 2019

Researchers define brain disorder that mimics symptoms of Alzheimer's disease

A brain disorder that mimics symptoms of Alzheimer's disease has been defined with recommended diagnostic criteria and guidelines for advancing future research on the condition.

30 Apr 2019

Researchers uncover potential clue to halt destruction of nerve cells in people with ALS

A special focus on rogue proteins may hold future promise in stopping the progression of nerve cell destruction in people who have amyotrophic lateral sclerosis or frontotemporal dementia.

24 Apr 2019

Researchers observe correlation between abnormal proteins and aggressive behavior in dementia

Researchers at Lund University in Sweden have together with American colleagues studied deceased patients who were diagnosed with Alzheimer's disease or frontotemporal dementia.

12 Apr 2019

Brain area that only processes spoken, not written words identified

Patients in a new Northwestern Medicine study were able to comprehend words that were written but not said aloud. They could write the names of things they saw but not verbalize them.

22 Mar 2019

Researchers show efficacy of new therapy for amyotrophic lateral sclerosis in mice

A team from Université Laval and the CERVO Brain Research Centre has demonstrated the efficacy in mice of a new therapy that addresses the main manifestation of amyotrophic lateral sclerosis.

7 Feb 2019

Study points to potential new biomarker and drug target for amyotrophic lateral sclerosis

Research led by stem cell scientists at Harvard University points to a potential new biomarker and drug target for amyotrophic lateral sclerosis, a neurological disease that is extremely difficult to diagnose and treat.

16 Jan 2019

Toxic protein assemblies found to play beneficial role in muscle generation

Toxic protein assemblies, or "amyloids," long considered to be key drivers in many neuromuscular diseases, also play a beneficial role in the development of healthy muscle tissue, University of Colorado Boulder researchers have found.

1 Nov 2018

Columbia scientist and collaborators receive $11.3 million to find new targets against brain disease

Anthony Fitzpatrick, PhD, a Principal Investigator at Columbia's Zuckerman Institute and Columbia University Irving Medical Center, together with scientists from the Mayo Clinic and Boston Children's Hospital, has been awarded $11.3 million to map the three-dimensional structures of protein tangles that accumulate in the human brain.

11 Oct 2018

Genervon reports new findings that drug candidate GM6 attenuates Alzheimer's disease in mice model

Following the closure of several research programs for Alzheimer's disease, in early 2018 the FDA issued a release entitled "Draft Guidance for Industry: Early Alzheimer's Disease: Developing Drugs for Treatment." Encouraged by the proposed changes in the new guidance, Genervon's research team reported new findings that its drug candidate GM6 attenuates Alzheimer's disease in an early AD transgenic APP mice model.

25 Sep 2018

Study shows that rogue proteins may underlie some ALS and frontotemporal dementia cases

ALS -- amyotrophic lateral sclerosis -- is a neurodegenerative disease that attacks motor neurons in the brain and spinal cord, slowly robbing its victims of their ability to walk, talk, breathe and swallow.

20 Aug 2018

PARP inhibitors show promise for treating and preventing brain disorders

A class of cancer drugs called PARP inhibitors could be useful for treating and preventing brain disorders, including amyotrophic lateral sclerosis, also called Lou Gehrig's disease, and some forms of frontotemporal degeneration, by halting the misplacement of specific proteins that affect nerve cells, according to a study published in Molecular Cell by researchers in the the School of Arts and Sciences and the Perelman School of Medicine at the University of Pennsylvania.

10 Aug 2018

Researchers identify new compound that protects against neurodegeneration

Researchers from the University of Liverpool have identified a new compound that protects against neurodegeneration in nematode worms. The discovery may enable novel treatments for human neurodegenerative diseases to be developed in the future.

18 Jul 2018

Targeting multiple proteins may be key to treat neurodegenerative disorders

Nearly all major neurodegenerative diseases - from Alzheimer's to Parkinson's - are defined and diagnosed by the presence of one of four proteins that have gone rogue: tau, amyloid-beta, alpha-synuclein, or TDP-43.

6 Jul 2018

Aquinnah Pharmaceuticals wins NINDS grant to advance novel therapies for ALS

Aquinnah Pharmaceuticals, leaders in stress granule biology, an exciting new target for the development of neurodegenerative therapeutics, announced today that it has been awarded $3.4 million from the National Institute of Neurological Disorders and Stroke in a competing grant to advance novel therapeutic drug candidates towards the clinic for treating patients with amyotrophic lateral sclerosis, also known as Lou Gehrig's disease.

21 Jun 2018

Small part of cellular protein that helps form long-term memories also drives neurodegeneration

Scientists have just discovered that a small region of a cellular protein that helps long-term memories form also drives the neurodegeneration seen in Amyotrophic Lateral Sclerosis (ALS). This small part of the Ataxin-2 protein thus works for good and for bad.

23 May 2018